Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (220 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-12-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Minimum age: 20 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bonewomenstatusstoppingtherapy
  Phrases that lowered it: to evaluatediseasesstudyproductsmedication
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 16.0% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Disease area, musculoskeletal: Yes (raises risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: 50 (lowers risk) · Who can join
• Drug's FAERS reports before start: 25289 (lowers risk) · Drug's FDA history
• Keywords listed: 5 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bisphosphonates for Prevention of Post-Denosumab Bone Loss NCT03396315 · started 2018 · scored riskier than 39% of active trials completed
• Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women NCT01440803 · started 2012 · scored riskier than 32% of active trials completed
• Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis NCT00926380 · started 2009 · scored riskier than 62% of active trials completed
• Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women NCT00697463 · started 2008 · scored riskier than 21% of active trials completed
• Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy NCT00919711 · started 2009 · scored riskier than 21% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.